Recently Featured

Roche to Acquire PathAI for $750 Million to Enhance AI in Pathology

May 9, 2026
Roche has signed a deal to pay $750 million upfront for Boston-based PathAI, marking a significant step for the Swiss pharmaceutical giant in its efforts to integrate artificial intelligence into pathology diagnostics. This acquisition is poised to accelerate Roche’s capabilities in leveraging AI technologies to assist pathologists in diagnosing diseases more efficiently and accurately. The…

FDA Approves Zenocutuzumab-zbco for Advanced Cholangiocarcinoma

May 9, 2026
On May 8, 2026, the Food and Drug Administration (FDA) granted approval for zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) aimed at treating adults with advanced, unresectable, or metastatic cholangiocarcinoma that exhibits a neuregulin 1 (NRG1) gene fusion and has shown disease progression following prior systemic therapy. This approval marks a significant advancement in the treatment options…

Human Drug Compounding Presents Both Medical Benefits and Risks

May 9, 2026
Compounded drugs play a critical role in addressing specific medical needs for patients who may not benefit from commercially available medications. These customized formulations are particularly vital for individuals with unique health conditions, allergies, or those requiring dosage adjustments. However, the practice of drug compounding is not without significant risks, including potential contamination and variability…

Former tobacco executive joins CDC senior leadership, raising concerns over industry influence

May 9, 2026
A former tobacco industry executive has been appointed to senior leadership at the Centers for Disease Control and Prevention, alarming public health advocates and critics of industry influence on government. Stephen Sayle, named in March as the CDC’s deputy director for legislative affairs, previously worked at Fontem Ventures, a subsidiary of the British multinational tobacco…

Ongoing Cases